- Home
- PNST vs AGEN Comparison
PNST vs AGEN Comparison
Compare PNST & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNST
- AGEN
- Stock Information
- Founded
- PNST 2007
- AGEN 1994
- Country
- PNST United States
- AGEN United States
- Employees
- PNST N/A
- AGEN N/A
- Industry
- PNST Blank Checks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PNST Finance
- AGEN Health Care
- Exchange
- PNST Nasdaq
- AGEN Nasdaq
- Market Cap
- PNST 111.5M
- AGEN 96.2M
- IPO Year
- PNST N/A
- AGEN 2000
- Fundamental
- Price
- PNST $0.90
- AGEN $2.72
- Analyst Decision
- PNST Strong Buy
- AGEN Buy
- Analyst Count
- PNST 3
- AGEN 3
- Target Price
- PNST $4.50
- AGEN $9.33
- AVG Volume (30 Days)
- PNST 55.4K
- AGEN 516.0K
- Earning Date
- PNST 11-26-2024
- AGEN 11-12-2024
- Dividend Yield
- PNST N/A
- AGEN N/A
- EPS Growth
- PNST N/A
- AGEN N/A
- EPS
- PNST N/A
- AGEN N/A
- Revenue
- PNST $123,579,000.00
- AGEN $160,427,000.00
- Revenue This Year
- PNST $25.96
- AGEN N/A
- Revenue Next Year
- PNST $19.30
- AGEN $0.04
- P/E Ratio
- PNST N/A
- AGEN N/A
- Revenue Growth
- PNST 11.06
- AGEN 59.00
- 52 Week Low
- PNST $0.56
- AGEN $2.58
- 52 Week High
- PNST $16.00
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- PNST 55.67
- AGEN 17.93
- Support Level
- PNST $0.83
- AGEN $2.98
- Resistance Level
- PNST $1.00
- AGEN $4.42
- Average True Range (ATR)
- PNST 0.09
- AGEN 0.28
- MACD
- PNST 0.03
- AGEN -0.13
- Stochastic Oscillator
- PNST 68.72
- AGEN 7.17
About PNST Pinstripes Holdings Inc.
Pinstripes Holdings Inc is an experiential dining and entertainment concept combining exceptional Italian-American cuisine with bowling, bocce, and private events. It owns and operates around 17 restaurants in the USA. The company designs and constructs large-format locations that are each 26,000 to 38,000 square feet of interior space, plus additional outdoor patio space that includes outdoor dining, bocce courts, fire-pits, and decorative fountains.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).